Concerning Omega-3 Brain Study

Stanfield concludes that the new ADNI study's negative result does not change his protocol because it omitted two decisive variables: supplement oxidation and B-vitamin status. He frames his approach as a triad: high-quality omega-3 + methylated Bs + TMG. The VITACOG trial had shown that B vitamins had no effect on brain atrophy when omega-3 was low, and conversely omega-3 without B vitamins may not help—or could even harm. He chose TMG (betaine) as an additional methyl donor to support homocysteine reduction. The protocol is his personal interpretation of the full evidence, not a randomized trial in itself.

The new study used the respected ADNI dataset and attempted to control for reverse causality by showing no baseline differences between future omega-3 users and non-users. The authors proposed that oxidized DHA (the most chemically vulnerable fat in the brain) might degrade mitochondrial function, explaining the drop in glucose metabolism. However, the dataset only captured self-reported omega-3 use as a yes/no variable, not supplement quality, oxidative status, storage conditions, or B vitamin/homocysteine levels. Stanfield argues that the result is real but incomplete—once you account for the two missing factors (rancidity and B-vitamin status), the interpretation changes completely. The VITACOG trial demonstrated that omega-3 is only beneficial when homocysteine is low, i.e., when B vitamin status is adequate. Without that measurement, the study likely obscured a nuanced interaction.